PCSK9 and cancer: Although the data supporting the use of PCSK9 inhibitors primarily as antilipidemic agent in patients with cancer is limited, preliminary data suggests that it may potentially assist anti-cancer therapy by boosting the effect of immunotherapy by upregulating the MHC-I expression and promoting intratumoral T-cell infiltration making the tumor more responsive to immunotherapy (86).